HBV therapeutic vaccine

HBV therapeutic vaccine
(CVI-HBV-002)

Therapeutic vaccine for the chronic hepatitis B patients and carriers

R&D Goals

Unmet medical needs

Rarely establish immunologic control over HBV; HBV clearance and HBsAg seroconversion required
Only applicable to the limited population of the chronically infected patients
Long-term risk of Viral resistance and Side effects related to the antiviral therapy exists
Significant treatment-failure population exists
Prevention of Re-infection and Relapse of the treated patients required

Features ofCVI-HBV-002

Therapeutic vaccine should activate the patient’s immune system effectively to fight and control the virus infection.
CVI-HBV-002 formulated with highly immunogenic L-HBsAg and powerful adjuvant L-pampo is designed to overcome the immune tolerance status of the chronic hepatitis patients.
Efficacy of CVI-HBV-002 as a therapthe immune tolerance status of the chronic hepatitis patientseutic vaccine was examined using HBsAg/HLA-A2 Tg mouse model. Immune response was induced under the immune tolerance status and HBsAg particles in the blood were decreased by the antibody induced. Study results published in Clinical Vaccine and Immunology (2012).
Clinical trial is on-going.